EGFR and neoplasm: Treatment was switched to alectinib, leading to significant tumor regression and partial response.<h4>Conclusion</h4>This case illustrates that in triple-positive NSCLC, initial EGFR-TKI combined with chemotherapy can achieve long-term control, while dynamic molecular profiling at progression is essential for identifying resistance mechanisms.